A

lexion Pharmaceuticals said Wednesday it is buying Sweden’s Wilson Therapeutics for $855 million to expand its pipeline of drugs to treat rare diseases, as the pace of deal-making in the biotech sector ticks higher.

The centerpiece of the Alexion transaction is Wilson’s lead drug WTX101, an oral agent in Phase 3 development as a treatment for Wilson disease, a rare, inherited disorder that causes liver and neurologic problems. WTX101 works by binding to copper in the bloodstream and promoting its removal in the liver.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.